Precursor B-cell acute lymphoblastic leukemia (B-ALL) represents a heterogeneous group of hematopoietic neoplasms with variable outcome. 1 The cytogenetic profiles, genotype and immunophenotype of the malignant cells have a considerable impact on prognostic stratifications with recognition of low, intermediate and high-risk groups. These stratifications, resulting in risk-adapted therapeutic regimens, underline the crucial importance of biological characteristics in the management of patients with ALL.
In contrast to acute leukemic presentation of Burkitt lymphomas, surface immunoglobulin (sIg) expression is typically absent on these precursor B-ALL cells. 1 In addition, Burkitt leukemia is classically associated with the FAB-L3 morphology and the presence of 8q24 (MYC) translocation. However, rare cases of sIg þ B-ALL with non-FAB-L3 morphology and lacking MYC rearrangement have been reported in both adult and pediatric patients as 'mature B-ALL'. 1, 2 Clonal rearrangements of MLL (mixed lineage leukemia or myeloid/lymphoid leukemia) gene are usually seen in infants' leukemias as well as a majority of therapy-related leukemias, in which it always represents a hallmark for aggressive disease, poor clinical outcome and bad response to treatment with high risk of relapse. 2, 3 Those rearrangements include chromosomal translocations, internal gene duplications, chromosome 11q deletions or inversions, MLL gene insertions into other chromosomes and insertion of genetic material into the MLL gene. 3 The most frequent translocation partner genes for MLL in acute leukemias are AF4, AF9, ENL, AF10 and AF6. In gene expression profiling studies, MLL þ precursor B-ALL shows a profile consistent with an early hematopoietic progenitor that is distinct from conventional B-ALL and acute myeloid leukemia, suggesting that MLL þ precursor B-ALL represents a clinically and molecularly unique entity. 3 Among the cases of mature B-ALL without FAB-L3 morphology and MYC rearrangement reported in children, very few present MLL gene rearrangements and especially the t(9;11) translocation. 2, 4, 5 We here describe an additional series of five cases of such childhood mature B-ALL with MLL rearrangement, four with the t(9;11) translocation and one with the t(10;11) translocation, and focus on their common clinical and biological characteristics.
Clinical data are summarized in Table 1 . A common feature in all cases was the presence of extramedullary involvement at diagnosis, including central nervous system (CNS; n ¼ 2) and renal tumorous enlargement (n ¼ 2). No skin or gums involvement was seen in these patients.
Hematological data are shown in Table 2 . All cases presented with marked blastic infiltration in peripheral blood and massive bone marrow leukemic infiltration with more than 80% of blast cells.
Morphological and cytochemical data are shown in Figure 1 and Table 2 . In the four cases with evidence of t(9;11) translocation, the bone marrow smears at diagnosis showed lymphoblasts with irregular nucleus, large and prominent nucleoli in some cells, microvacuolated cytoplasm without hyperbasophilic aspect and small to intermediate size (15-20 mm). In the case with t(10;11) translocation, the predominant leukemic cells had a round nucleus with lacy chromatin pattern and a small amount of cytoplasm. They were larger than the blast cells with t(9;11) translocation (about 25 mm), but did not appear to present any monocytic differentiation.
No FAB-L3 morphology was present in any of these cases (see Figure 1a) . Blast cells exhibited a high mitotic index. However, no apoptotic figure was seen, confirming the absence of Burkitttype morphology criteria. Myeloperoxydase reaction was negative both at diagnosis and relapse in all patients. Alphanaphthyl-butyrate esterase was performed at diagnosis in only one case and was negative. The blast cells morphology and cytochemistry remained unchanged at relapse (cases 2, 3 and 4) with no switch to FAB-M5-monocytic aspect.
Blast cells exhibited a mature B-cell immunophenotypic profile, that is, CD19 þ , CD20 low , CD22 þ , cIg þ , sIg þ with ml isotype in three patients and mk isotype in two, CD34À, TdtÀ and CD10 þ /À in all of the cases (see Table 3 ). Myeloid and monocytic markers were all negative.
In one case (case 4), some T-cell markers were present at relapse (CD2 and CD5) with a low positivity. In all cases with evidence of relapse, light-chain isotype and maturity B-cell markers remained unchanged when compared to those at diagnosis.
Despite the presence of MLL rearrangement in all cases, no phenotypic switch to a monocytic leukemia has been noted during the disease evolution.
Results of chromosome studies for the five patients are summarized in Table 3 . Cases 1, 2, 3 and 4 had a t(9;11)(p22;q23) translocation and case 5 had a t(10;11)(p12;q23) translocation. Conventional karyotyping with R-banding, H-banding, G-banding showed normal results in cases 1, 3, 4 and 5. In case 2, a t(9;11) translocation was suspected in front of a very pale aspect of the extremity of chromosome 11 long arm (11q23) associated with increased density of short arm of chromosome 9 (9p21-22). This result was confirmed by molecular analysis (Southern blot) that showed AF9-MLL fusion gene (see below).
MLL rearrangement was studied and detected by fluorescence in situ hybridization (FISH) analysis using an MLL probe in cases 1, 2, 3 and 5, whereas it was found at relapse, but not studied at diagnosis in case 4. In case 1 and 3, the MLL partner gene was identified through a simultaneous hybridization with 11q23-MLL and BCR-ABL probes on bone marrow cells. No evidence of MYC (8q24) rearrangement was detected in all cases with FISH methods.
Finally, relapse karyotypes were similar to that at diagnosis, with no supplemental clonal abnormality.
Minimal residual disease (MRD) was assessed during all the treatment procedure by reverse transcription-PCR. MRD could be followed in all cases except case 2 because of nonavailability of this technique at time of diagnosis. In the cases where MRD could be determined, results were all negative at the end of the induction phase (between day þ 35 in case 1 and day þ 46 in case 3), and remained so during the intensification and consolidation phases. In case 2, relapse occurred only 4 months after the last negative molecular MRD, suggesting a very fast clonal leukemic evolution.
The patients were treated according to age-and risk-adjusted protocols available in different periods of time (from 1994 to 2005). Response to therapy, occurrence of relapse and overall survival are summarized in Table 1 . Letters
Patient 2 received induction therapy according to the group C of LMB89 trial. Rapid response was observed with resolution of organomegaly and hyperleukocytosis, and CR was documented at day þ 30. A relapse occurred 2 months after the last course of chemotherapy with massive marrow, CNS and hepatosplenic involvement. Second-line chemotherapy achieved a new CR and unrelated bone marrow transplantation was performed. Two months after transplantation, the patient developed adenoviral systemic disease and died with multi-organ failure.
Patients 3 and 5 were treated according to the INTERFANT 99 trial. In both cases, CR was documented after the end of induction phase on bone marrow smears. The first patient relapsed with testicular involvement 14 months after diagnosis. A second-line treatment consisted of orchidectomy, chemotherapy associated with radiotherapy on controlateral testis. After two courses of chemotherapy, the patient received unrelated 6/6 cord blood transplantation, but died of adenovirus-associated pneumonia after 35 days. The second patient was off-therapy for 2 years. Bone marrow smears at the end of treatment showed CR and MRD evaluation at this time was negative. No evidence of relapse has been found so far and the patient is doing well.
The two patients who have not presented any relapse so far are disease free 4 months and 2 years after the end of maintenance therapy.
Mature B-ALL is a rare entity and accounts for 1-2% of all children ALL. 1, 4 This subset has been identified in the European Group for the Immunological Characterization of Acute Leukemias classification and is characterized by expression of pan-B-cell markers and sIg with light-chain restriction (sIg þ B-ALL). It is most frequently associated with Burkitt/FAB-L3 morphology and the presence of 8q24 (MYC) rearrangements. However, in some rare situations, sIg þ B-ALL cases present as morphology similar to precursor B-ALL (FAB-L1/L2) and absence of 8q24/MYC translocation. The five more cases of MLL þ sIg þ B-ALL we report here emphasize the fact that not all acute leukemias with sIg expression exhibit FAB L3 morphology and that sIg þ ALL is not always associated with translocations at 8q24 (MYC).
Among our five cases of MLL þ sIg þ B-ALL, four are associated with t(9;11)(p22;q23) and one with t(10;11) (p12;q23). These cases share the same clinical and biological characteristics as described previously in the literature: 2, 4, 5 hyperleukocytosis (median value of white blood cell count at 56 Â 10 9 l À1 ), extramedullary localizations with skin, kidneys, CNS, liver and spleen involvement (all patients had at least one of those localizations at presentation) and young age (less than 2 years). The phenotype was also comparable to previous cases with negativity of immaturity markers (CD34À, TdtÀ) and positivity of CD79a, CD79b, CD19 associated with sIg expression. The main difference was the absence in our series of any light-chain restriction. Interestingly, the case showing t(10;11) presented the same features as cases with t(9;11) with renal enlargement, skin lesions and same sIg þ , CD34À and TdtÀ phenotype. Both age at presentation and clinical characteristics are typical of ALL with MLL translocation. This illustrates that molecular abnormalities, particularly involving MLL, are more important determinants of disease behavior than immunophenotype.
The t(9;11) translocation produces an AF9-MLL chimera while t(10;11) translocation produces an abnormal AF10-MLL gene product. AF9 and AF10 have been recently characterized as components of a Pol II transcription elongation factor b (P-TEFb) kinase suggesting cooperative functions. 6 In the cases we analyzed, the cytogenetic study by conventional karyotyping was reported to be normal in four cases out of five. The only case where the t(9;11) translocation has been suspected on karyotype has been confirmed by state-of-the-art FISH and molecular analysis. Two-step FISH assay using MLL and AF9 probes has recently been validated in 96 cases of acute myeloid leukemia 7 and appears as a reliable method for the identification of MLL/AF9 fusion in interphase cells, allowing for a reclassification of cases with suboptimal chromosome morphology. This technique would be useful in mature B-ALL with MLL rearrangement to identify sooner than molecular biology MLL-AF9 fusions at diagnosis.
For cases with t(10;11), no specific probe targeting AF10 has been described so far and molecular biology techniques remain the only way to identify the fusion gene to follow MRD during the treatment.
Morphologic and phenotypic lineage switching from B-ALL to monocytic/monoblastic leukemia between diagnosis and relapse is classically observed in B-precursor B-ALL cases bearing the t(4;11)/AF4-MLL. 8 Interestingly, we did not observe this phenomenon in our MLL þ sIg þ , mature B-ALL cases. This absence of clonal evolution despite MLL rearrangement suggests that bipotential B progenitor cells are not systematically involved in mature B-ALL MLL þ bone marrow. Table 3 Phenotypic and cytogenetic findings at diagnosis on the five patients with mature B-cell acute lymphoblastic leukemia and mixed lineage leukemia or myeloid/lymphoid leukemia rearrangement CD19 CD20 CD22 CD10 cCD79a CD79b CD34 Abbreviations: MLL, mixed lineage leukemia or myeloid/lymphoid leukaemia; nd, not done.
Letters to the Editor
Concerning response to treatment and overall prognosis, all patients experienced a complete response to induction therapy with rapid decrease in leukocytosis and resolution of extramedullary involvement under corticosteroid therapy. MRD, when applicable, was found negative at the end of induction, underlying high sensitivity to chemotherapy. This high chemosensitivity contrasted with the high incidence of relapse (occurring in three of our cases) and poor overall prognosis. This finding underlines the importance of quick identification of this rearrangement to propose treatment adaptation to high-risk groups, including allogeneic marrow transplantation consideration before facing potentially chemoresistant relapse.
In summary, we describe here five cases of mature 'sIg þ ' B-ALL with non FAB-L3 morphology displaying 11q23-MLL rearrangement, and especially t(9;11), occurring in young children with a poor prognosis and requiring treatment intensification. clone either persisted or became clinically manifest as PMF [2] [3] [4] or PV. 5 In our previously reported case, a minor JAK2 V617F clone expanded after major response of Ph þ -CML to IM. 2 In search for parallel cases, we discovered a total of four CMPD cases of concurrent BCR-ABL and JAK2 V617F mutation in the Hannover bone marrow registry (Table 1 ). In one of these Ph þ -CML cases similar to the previously published cases, 2-5 the concurrent JAK2 V617F clone became clinically manifest subsequently to IM-induced suppression of the BCR-ABL clone. In another case, a shift of phenotype from CML to JAK2 V617F -positive PMF occurred during treatment with IM. One longlasting JAK2 V617F -positive PV case acquired the BCR-ABL aberration and in one Ph þ -CML case, the JAK2 V617F clone was clinically silent. Remarkably, the majority of patients with concurrent BCR-ABL and JAK2 V617F reported up to now, including this series, were male (Table 1) .
Previously established methods for molecular analysis of formalin-fixed and paraffin-embedded bone marrow (BM) biopsies were used for the detection of BCR-ABL transcripts and pyrosequencer assay was used for the quantification of JAK2 V617F and MPL W515L/K mutant allele frequencies.
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